2018 Worldwide Contraceptives Market Research Report adds report Global Contraceptives Market 2014-2018 to its store. Recently, pharmaceutical companies have introduced new products into their portfolios or diversified their contraceptive drugs and devices. This trend has been primarily supported by several prominent deals or partnerships to develop or introduce new products with better efficacy and safety profiles. These strategic decisions will help companies to generate revenue and acquire a significant share of the Global Contraceptives market. Some of the major acquisitions in this space include Conceptus Inc. by Bayer, Warner Chilcott plc by Actavis, Uteron Pharma SA by Watson Pharmaceuticals Inc., and Barr Pharmaceuticals Inc. by Teva Pharmaceutical Industries. Some of the other prominent deals include Bayer and USAID partnering to make Microgynon, an oral contraceptive and Starpharma Holdings licensing agreement with Okamoto Industries Inc. for the VivaGel-coated condom.

According to the report, the Global Contraceptives market is driven by several factors, of which the growing prevalence of unplanned pregnancies is one of the major drivers. In order to control the 41 percent of unplanned pregnancies out of 208.2 million pregnancies globally, there has been an increase in the number of initiatives by governments and NGOs.

Contraception, also known as birth control or fertility control, refers to the use of methods or drugs or devices to prevent pregnancy as a consequence of sexual intercourse. Contraception methods can be temporary and permanent and are available to men and women. Permanent methods include male sterilization (vasectomy), and female sterilization including tubal occlusion or hysteroscopic sterilisation. Temporary methods can be hormonal and non-hormonal. The non-hormonal methods include condoms, diaphragms, sponges, withdrawal methods, cervical caps, and non-hormonal IUDs. Condoms, diaphragms, sponges, and cervical caps are also referred to as barrier contraception methods. Hormonal methods include oral contraceptive pills, contraceptive transdermal patches, vaginal rings, hormonal IUDs, and vaginal implants. Hormonal methods contain synthetic sex hormones estrogen/progestin or a combination of both which prevent ovulation and thicken cervical mucus in the female. Currently, hormonal methods can only be used by women. The development of a male hormonal contraceptive is an active research area.

Analysts forecast the Global Contraceptives market will grow at a CAGR of 5.90 percent over the period 2013-2018.

Covered in this Report

The Global Contraceptives market can be segmented broadly into two divisions: Drugs and Devices. This report covers the present scenario and the growth prospects of the Global Contraceptives market for the period 2013-2018. To calculate the market size, the report considers revenue generated from the sales of various products used for contraception which include:

  • Drugs (Oral Contraceptive Pills, Injectable Contraceptives, Topical Contraceptives)
  • Devices (Male & Female condoms, Diaphragms, IUDs, Vaginal Rings, Female Sponges and Subdermal Contraceptive Implants)

Purchase Report Directly @

Global Contraceptives Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Contraceptives market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • EMEA
  • APAC
Analyst recognizes the following companies as the key players in Global Contraceptives Market: Actavis plc, Bayer AG , Johnson & Johnson’s Janssen Pharmaceuticals, Inc., Merck & Co., Pfizer, Inc., Teva Pharmaceutical Industries, Ltd, Adamis Pharmaceuticals, Corp., Agile Therapeutics, Inc., ANI Pharmaceuticals,Inc., Ansell Ltd., Apothecus Pharmaceutical Corp., Blairex Laboratories Inc., Church & Dwight, Co. Inc., Caldwell Consumer Health, LLC., Ferring International Center S.A, Fuji Latex Co., Ltd., HL LLifecare Limited, Mayer Laboratories , Medicines 360, Karex Berhad , Lipocine Inc., Lupin Pharmaceuticals, Inc., Mylan Laboratories Inc., Okamoto Industries, Inc., Pantarhei Bioscience B.V., Paul Hartmann AG, Reckitt Benckiser Group Plc, The Female Health Company.

Key Market Driver
  • Growing Prevalence of Unwanted Pregnancies.

Key Market Challenge

  • Growing Prevalence of Unwanted Pregnancies.
  • Introduction of Cheap Generic Contraceptives

Key Market Trend

  • Increasing Strategic Partnerships.

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

About Us: is an online market research reports library of 350,000+ in-depth studies of over 5000 micro markets. Call +1 888 391 5441 with your research requirements or email the details on and we would be happy to help you find the business intelligence that you need. Not limited to the Health and Wellness Market offers research studies on agriculture, consumer goods, environment, advanced materials, public sector, food and beverages, energy and power, medical devices, healthcare, automotive, manufacturing & construction, semiconductor and electronics, IT & telecommunication, pharmaceuticals, retail, water, banking and financial services , advanced materials and much more.